Heterocyclic Compounds

Matches 551 - 600 out of 54,142	< 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 >

Document	Document Title
WO/2023/235618A1	FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific covalent inhibitors of a menin or menin-MLL interaction. Also disclosed are pharmaceutical composit...
WO/2023/232069A1	AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF An azaquinolinone compound having a structure of the following formula (I) as an enzyme inhibitor for the poly(ADP-ribose)polymerase (PARP) family, and a pharmaceutically acceptable salt, a stereoisomer, a tautomer or an N-oxide drug the...
WO/2023/232130A1	HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF Disclosed in the present invention are a heterocyclic compound as shown in formula (I) or a stereoisomer, deuterated compound, solvate, pharmaceutically acceptable salt, or co-crystal thereof and a pharmaceutical composition thereof, and...
WO/2023/235384A1	COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME Disclosed herein are new aromatic compounds, compositions that include one or more aromatic compounds, and methods of synthesizing the same. Also disclosed herein are methods of enhancing readthrough of genes containing premature termina...
WO/2023/234425A1	AMINO ACID ACTIVE ESTER AND SALT THEREOF The present invention provides a novel active ester of an amino acid to be used for amino acylation of tRNA, said ester being capable of reducing risks to safety and waste. The present invention provides a compound represented by formula...
WO/2023/226679A1	3C-LIKE PROTEASE INHIBITOR The present invention provides a 3C-like protease inhibitor represented by formula (I), or a pharmaceutically acceptable salt or ester thereof, and a stereoisomer or tautomer, a racemate, a nitrogen oxide, a polymorph, a hydrate, a solva...
WO/2023/230205A1	MEK INHIBITORS AND USES THEREOF The present disclosure provides MEK inhibitors, compositions thereof, and methods of using the same.
WO/2023/230609A1	HETEROCYCLIC PAD4 INHIBITORS The disclosure generally relates to compounds of Formula I, comprising a 1,6,7,8-tetrahydro-5H-imidazo[4,5-g][1,6]isoquinolin-5-one moiety directly bonded to an azaindole or indole moiety, such compounds as inhibitors of PAD4, methods fo...
WO/2023/230480A2	COMPOUNDS AND METHODS FOR THE TREATMENT AND PREVENTION OF HIV Compositions and methods for treating HIV using compounds that sensitize HIV‐1 infected cells to antibody-dependent cellular cytotoxicity.
WO/2023/229430A1	HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF The present invention relates to a heteroaryl derivative and uses thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, and thus can be effectively used as a therapeutic agent fo...
WO/2023/229322A1	METHOD FOR PREPARING 6-METHOXYPYRIDIN-3-YL DERIVATIVES The present invention relates to a method for preparing 6-methoxypyridin-3-yl derivatives. The preparation method according to the present invention has the advantage of allowing the reaction to be conducted under mild conditions that en...
WO/2023/227125A1	NEW FUSED-HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF Disclosed in the present invention is a new fused-heterocyclic compound having target inhibitory activity for CDKs, and specifically disclosed is a compound having a structure as represented by formula (I) as a target inhibitor for CDKs ...
WO/2023/229323A1	METHOD FOR PREPARING 6-METHOXYPYRIDIN-3-YL DERIVATIVE The present invention relates to a method for preparing a 6-methoxypyridin-3-yl derivative. The preparation method according to the present invention has an advantage in that the reaction can be carried out under mild conditions which en...
WO/2023/227080A1	PROTAC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF Provided are a PROTAC compound, a pharmaceutical composition containing same, and a preparation method therefor and the use thereof. The PROTAC compound has a structure as represented by formula (I), and can be used for treating BTK-rela...
WO/2023/227117A1	3C-LIKE PROTEASE INHIBITOR Provided in the present invention is a 3C-like protease inhibitor as shown in formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate or solvate thereof. Also provided in ...
WO/2023/226965A1	ROCK INHIBITORS AND USES THEREOF Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as ROCK inhibitors. Also disclosed are pharmaceutical compositions comprising a compound of Formula (I), and methods of using s...
WO/2023/229375A1	HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF The present invention relates to a heterocyclic compound represented by chemical formula 1, exhibiting a diacylglycerol kinase inhibitor activity, a pharmaceutical composition comprising same as an active ingredient, and use thereof.
WO/2023/230477A1	PYRIDINE CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a. subject in need a. therapeutically effective amount of a Chk1 inhibitor disclosed herein.
WO/2023/227946A1	TYK2 INHIBITORS AND USES THEREOF Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, disease...
WO/2023/227052A1	BICYCLIC DERIVATIVE PARP INHIBITOR AND USE THEREOF Disclosed herein are a compound represented by formula (II) or a stereoisomer, a pharmaceutically acceptable salt, a solvate, a co-crystal or a deuterated form thereof, or a pharmaceutical composition comprising same, and use thereof as ...
WO/2023/226323A1	QUINAZOLINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to the technical field of chemical medicine, and in particular to a quinazoline derivative, and a preparation method therefor and the use thereof. The quinazoline derivative provided by the present invention...
WO/2023/220831A1	HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kina...
WO/2023/222115A1	HYDROXYAMIDE DERIVATIVE AND USE THEREOF Provided in the present application is a hydroxyamide derivative represented by formula (I), and a tautomer, stereoisomer, solvate, metabolite, isotopically-labeled compound, pharmaceutically acceptable salt or co-crystal thereof. The co...
WO/2023/225588A2	NOVEL ISOQUINOLONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR THERAPEUTIC USE Aspects of this invention are related to novel compounds of Formula I and compositions thereof that are inhibitors of glycogen synthase kinase 3 beta (GSK3[3). Some aspects of the invention relate to novel compounds and compositions havi...
WO/2023/224853A1	AT2R ANTAGONISTS AND USES THEREOF This invention provides certain piperidine compounds as AT2R antagonists, e.g., compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and X are as defined herein, pharmaceutical compositions thereof,...
WO/2023/225162A1	ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF The present disclosure relates to indolinyl compounds. The present disclosure further relates to compounds that inhibit viral helicase-primase. The present disclosure further relates to the use of the compounds for the preparation a medi...
WO/2023/222137A1	NOVEL TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUND, AND USE THEREOF Provided are a novel tetrahydroisoquinoline compound, a preparation method therefor, a pharmaceutical composition containing said compound, and a use thereof. Specifically, provided are a nitrogen-containing heterocyclic compound as repr...
WO/2023/225601A2	RIPK2 AND NOD INHIBITORS Substituted phenylpyridine compounds are disclosed. Also disclosed is the use of the phenylpyridine compounds in methods of treatment and for inhibiting RIPK2 and/or NOD2 cell signaling.
WO/2023/223099A2	PRMT5 INHIBITORS AND METHODS OF TREATMENT The present invention relates to protein arginine N-methyltransferase-5 inhibitors and more specifically to substituted quinazoline-2,4 compounds useful as such agents. These inhibitors are useful as anti-cancer agents.
WO/2023/221419A1	CRYSTAL FORM OF VONOPRAZAN PYROGLUTAMATE AND PREPARATION METHOD THEREFOR The present invention relates to a crystal form of Vonoprazan pyroglutamate and a preparation method therefor. The crystal form of Vonoprazan pyroglutamate obtained in the present invention not only has good solubility, but also has exce...
WO/2023/222124A1	5,6-DIHYDRO-1,2,4-TRIAZINE COMPOUND AND PHARMACEUTICAL USE THEREOF AS GLP-1 RECEPTOR AGONIST Disclosed in the present invention are a 5,6-dihydro-1,2,4-triazine compound and the pharmaceutical use thereof as a GLP-1 receptor agonist. A structure of the 5,6-dihydro-1,2,4-triazine compound is represented by formula (I), and in the...
WO/2023/222558A1	PRECURSOR AND THERANOSTIC RADIOTRACER WITH IMPROVED TUMOR RETENTION A precursor compound for a therapeutic, FAP-targeted radiotracer comprises a chelator Ch for complexation of a radioisotope and one, two, three or four targeting vectors TV1, TV2, TV3, TV4, which independently of one another comprise a m...
WO/2023/225625A2	BIFUNCTIONAL DEGRADERS COMPRISING ELECTROPHILIC PROTACS THAT ENGAGE DCAF1 AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME Disclosed are bifunctional degraders comprising electrophilic PROTACs that engage DCAF1 and pharmaceutical compositions comprising the same. The bifunctional degraders are of Formula A-B-C wherein, A is a ligand to a protein of interest,...
WO/2023/222644A1	PYRAZOLE DERIVATIVES AS STING AGONISTS The present invention provides novel compounds having the general formula (I) wherein ring A, ring B, ring C, bond a, and R1 to R7 are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compoun...
WO/2023/224981A1	HSD17B13 INHIBITORS AND USES THEREOF Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
WO/2023/222019A1	LIGAND-DRUG CONJUGATE AND USE THEREOF Provided are a ligand-drug conjugate and use thereof. Specifically, provided are a ligand-drug conjugate represented by formula I or a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutic...
WO/2023/217230A1	KINESIN KIF18A INHIBITOR AND USE THEREOF The present invention provides a KIF18A inhibitor and a method for synthesizing same. The compound of the present invention can regulate KIF18A protein to influence the cell cycle and the cell proliferation process, so as to treat cancer...
WO/2023/217124A1	FLUORESCENT MOLECULE, AND MULTICOLOR SYSTEM AND PREPARATION METHOD THEREFOR AND USE THEREOF Provided are a fluorescent molecule, and a multicolor system and a preparation method therefor and the use thereof. The structure of the fluorescent molecule is as shown in (I), where n is an integer from 0 to 12. The system comprises th...
WO/2023/217148A1	AROMATIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF Disclosed are an aromatic compound, a method for preparing same, and use thereof. Specifically, the present application discloses a compound represented by formula I or a pharmaceutically acceptable salt thereof and use thereof. The arom...
WO/2023/220225A1	INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS The present disclosure is directed to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, and their use for the treatment of hRSV and hMPV.
WO/2023/220180A1	METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS Disclosed herein are methods of manufacturing pyridazinone compounds useful in the treatment of Duchenne Muscular Dystrophy using Suzuki cross-coupling reactions.
WO/2023/217045A1	FLUOROQUINOXALINONE DERIVATIVE FOR SELECTIVELY INHIBITING PARP1 Disclosed is a series of fluorine-substituted heterocyclic compounds, and specifically, disclosed are a compound represented by formula (XII) and a pharmaceutically acceptable salt thereof.
WO/2023/217184A2	SUBSTITUTED PYRIDINE OR PYRIMIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD, AND USE The present disclosure relates to a substituted pyridine or pyrimidine derivative and a use thereof. Specifically, provided are a substituted pyridine or pyrimidine compound represented by formula (I) or a pharmaceutically acceptable sal...
WO/2023/217156A1	POLYCYCLIC COMPOUND AND USE THEREOF A polycyclic compound, a preparation method therefor, and the use thereof in the prevention and/or treatment of proliferative diseases. The compound has a structure as represented by formula (I):
WO/2023/217539A1	ANTIVIRAL COMPOUNDS AND COMPOSITIONS THEREFROM The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. It also relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in medicine, in particular for t...
WO/2023/218195A1	GCN2 INHIBITORR The invention provides compounds of formula (I) Wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds...
WO/2023/217077A1	PHENYLPYRAZOLE COMPOUND AND APPLICATION THEREOF Disclosed are a phenylpyrazole compound and an application thereof. The structure of the compound is as shown in general formula (I), and the definitions of the various substituents in the formula are given in the description. Also discl...
WO/2023/219952A1	MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF Described herein are radiotherapeutics that target tumor cells expressing the melanocortin type 2 receptor (MC2R) and their use in the treatment and/or diagnosis of cancer.
WO/2023/217203A2	PREPARATION METHOD FOR DIPHENYL PYRAZOLE COMPOUND The present invention provides a new preparation method for a diphenyl pyrazole compound. The preparation method of the present invention has low costs and high safety, and is very suitable for industrial production.
WO/2023/219879A1	SOLID FORM OF PPAR-gamma MODULATORS AND METHODS OF USE The disclosure provides novel solid state Form A of Compound I, compositions comprising the same, and methods of using the same, including use in treating cancer, particularly cancers in which agents that target the RXRα and/or PPARγ p...

Matches 551 - 600 out of 54,142	< 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 >